Digital AI healthcare company
Sword Health is a digital musculoskeletal (MSK) therapy company founded in 2015 by Virgilio Bento in Porto, Portugal. The platform combines FDA-cleared motion-tracking hardware, computer-vision and AI with a human licensed physical therapist to treat chronic and acute MSK conditions remotely.
Employers and health plans - not individuals - are the primary buyers in the US, where MSK is one of the single largest drivers of health spend.
Sword reached unicorn status in 2021 and has continued to raise at higher valuations - a 2024 round valued the company at approximately $3B, led by General Catalyst. Investors include Khosla Ventures, Sapphire Ventures, Oak HC/FT, Founders Fund, Bond and Comcast Ventures.
The company serves hundreds of US employers and health plans covering millions of lives and has launched adjacent products - Bloom for women's pelvic health, Mind for behavioural health, and Phoenix for its AI care layer. The legal parent is Sword Health, Inc., a Delaware C-Corp; Portuguese engineering, AI and clinical-operations teams sit under Sword Health, S.A. in Porto and Lisbon.
Sword Health is the Porto-founded digital-health unicorn that has done more than any other Portuguese company to demonstrate you can sell a regulated US healthcare product from a European engineering base.
Virgilio Bento built the early hardware and AI in Porto, but the company's commercial model is overwhelmingly US - selling to self-insured employers and health plans that pay per-engaged-member per month to reduce MSK surgical and specialist spend.
That commercial reality forced an early decision: the fundraising parent had to be Sword Health, Inc., a Delaware C-Corp, because US employer health-benefits buyers and US institutional investors expect to contract with and invest in a US entity.
Below that parent sits Sword Health, S.A. - a Portuguese company that employs the physical therapists serving European customers, the AI/computer-vision research team, and much of the software engineering organisation.
The structural pattern is the same as OutSystems, Talkdesk, Feedzai and Remote: Delaware on top, Portugal underneath, intercompany services and IP agreements bridging the two, SIFIDE II R&D credits claimed against Portuguese corporate tax.
What differs is the regulatory layer - Sword's hardware products needed FDA clearance, and its clinical services require state-by-state PT licensing in the US, which the Delaware entity contracts separately.
The company is also a useful illustration of Lisbon-via-Porto talent dynamics. Web Summit in Lisbon helped route US VC attention to Sword, and NHR (until 2024) made it attractive to relocate senior leaders from the US and UK. Remote, the EOR unicorn also in Lisbon, is essentially productising the payroll plumbing Sword had to build to hire US clinical operators from a Portuguese-parented structure.
Sword's 2024 round, with revenue reportedly approaching $100M and AI costs falling, positions it as a credible IPO candidate in the 2025-2027 window.
Yes. Sword crossed unicorn status in 2021 and was valued at approximately $3B in a 2024 round led by General Catalyst.
It provides digital physical therapy for musculoskeletal conditions via motion-tracking hardware, computer vision and a licensed PT, sold to US employers and health plans.
Founded in Porto by Virgilio Bento. Most engineering and AI research sits in Porto and Lisbon, but the legal parent is a Delaware C-Corp.
The device clearances are held by the US corporate entity, Sword Health, Inc., which is the registered 510(k) applicant.
